Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933559 | 0.83 | CA1 (0.40) | CA1CA2CA9CA7CA13 | |
| SCHEMBL309951 | 0.78 | CES1 (0.33) | — | |
| SCHEMBL353498 | 0.76 | ESR1 (0.32) | — | |
| SCHEMBL216634 | 0.74 | APP (0.46) | — | |
| SCHEMBL14814813 | 0.74 | ALDH1A1 (0.35) | — | |
| SCHEMBL7204059 | 0.74 | CA2 (0.33) | CA2ARG1 | |
| SCHEMBL14814810 | 0.74 | — | — | |
| SCHEMBL3097818 | 0.74 | — | — | |
| SCHEMBL10457263 | 0.73 | CA2 (0.43) | CA1CA2CA9CA7 | |
| SCHEMBL10405537 | 0.73 | CA2 (0.39) | CA1CA2CA9CA7ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019046465-A2 | THERAPEUTIC INDOLES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-07 | — | — | WO | claimed |
| US-10392348-B2 | 2-oxo-3,4-dihydroquinoline compounds as plant growth regulators | SYNGENTA PARTICIPATIONS AG (CH) | 2019-08-27 | — | — | US | disclosed |
| WO-2019046465-A2 | THERAPEUTIC INDOLES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20180044297-A1 | 2-OXO-3,4-DIHYDROQUINOLINE COMPOUNDS AS PLANT GROWTH REGULATORS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-02-15 | — | — | US | disclosed |
| CN-101177385-B | Aryl sulfonic acid amides and analogues as well as its purpose in curing neural degeneration disease | BAYER AG | 2011-06-15 | — | — | CN | disclosed |
| CN-100453529-C | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2009-01-21 | — | — | CN | disclosed |
| CN-101177385-A | Aryl sulfonic acid amides and analogues as well as its purpose in curing neural degeneration disease | BAYER AG (DE) | 2008-05-14 | — | — | CN | disclosed |
| CN-100371318-C | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2008-02-27 | — | — | CN | disclosed |
| CN-1754873-A | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2006-04-05 | — | — | CN | disclosed |
| EP-1105370-B9 | NOVEL ARYL SULPHONAMIDES AND ANALOGUES | BAYER HEALTHCARE AG (DE) | 2005-01-12 | — | — | EP | disclosed |
| US-6573278-B2 | For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| US-20030073727-A1 | Novel arylsulphonamides and analogues | MITTENDORF JOACHIM (DE) | 2003-04-17 | — | — | US | disclosed |
| US-6545050-B1 | Prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity. | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-08 | — | — | US | disclosed |
| EP-0966436-B1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | BAYER AG (DE) | 2002-12-11 | — | — | EP | disclosed |
| US-6469054-B1 | PROPHYLAXIS AND TREATMENT OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR FOR THE TREATMENT OF CEREBRAL APOPLEXY, CRANIOCEREBRAL TRAUMA, PAIN AND SPASTICITY | BAYER AKTIENGESELLSHAFT (DE) | 2002-10-22 | — | — | US | disclosed |
| EP-1230210-A1 | AMINOALCOHOL DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-14 | — | — | EP | disclosed |
| US-20020072529-A1 | Arylsulfonamides and analogues | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2002-06-13 | — | — | US | disclosed |
| US-6262112-B1 | 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
| WO-2001036375-A1 | AMINOALCOHOL DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-25 | — | — | WO | disclosed |
| CN-1253545-A | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2000-05-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392348-B2 | 2-oxo-3,4-dihydroquinoline compounds as plant growth regulators | CDC25B, OSR1, CDC25C | CA1 4131/4885CA2 1966/4885CA9 4525/4885 |
| US-20030073727-A1 | Novel arylsulphonamides and analogues | PRSS12, OPRL1, CTSH | CA1 4138/4885CA2 4123/4885CA9 4576/4885 |
| US-20180044297-A1 | 2-OXO-3,4-DIHYDROQUINOLINE COMPOUNDS AS PLANT GROWTH REGULATORS | CDC25B, OSR1, CDC25C | CA1 4131/4885CA2 1966/4885CA9 4525/4885 |
| US-20020072529-A1 | Arylsulfonamides and analogues | ARSA, PRSS12, SNCA | CA1 1982/4885CA2 3918/4885CA9 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.